What is the current price and pre-market move for AYA.AX stock?

AYA.AX stock is trading pre-market at A$3.56, down 4.81% on 03 Feb 2026. Volume is higher than average at 876,486 versus avg 799,066, which signals active trading ahead of earnings.

What are Meyka AI's forecasts for AYA.AX stock?

Meyka AI's forecast model projects a monthly target of A$4.06 and a 1-year target of A$7.30 for AYA.AX stock. The 1-year target implies an upside of approximately 105.05% from the current price A$3.56.

What are the main risks for investors in AYA.AX stock?

Key risks for AYA.AX stock include negative EPS (−0.18), very high price-to-sales, low revenue base, regulatory and clinical hurdles in the U.S., and execution risk on commercial rollouts that could delay revenue conversion.

How does Artrya's valuation compare to healthcare peers?

Artrya's trailing metrics show a price-to-book of 17.09 and price-to-sales of 14286.41, far above sector medians. Compared with the Australian Healthcare average PE near 22.40, Artrya is priced for future growth rather than current earnings.

AU Stocks

AYA.AX Artrya Limited ASX -4.81% pre-market 03 Feb 2026: U.S. expansion catalyst

ByHuzaifa Zahoor February 2, 2026February 2, 2026

AYA.AX stock opens pre-market at A$3.56, down 4.81% on 03 Feb 2026 after trading between A$3.37 and A$3.57 earlier. Artrya Limited (AYA.AX) reported Q2 2026 commentary focused on scaling in the U.S., and volume of 876,486.00 shares suggests active interest ahead of the February earnings call. We use Meyka AI as an AI-powered market analysis platform to link the company update to valuation, technicals and short-term catalysts in the Australian Healthcare AI sector.